サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1409505

肥大型心筋症（HCM）治療薬の世界市場レポート 2024年

Hypertrophic Cardiomyopathy (HCM) Therapeutics Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
肥大型心筋症（HCM）治療薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

肥大型心筋症（HCM）治療薬の市場規模は近年着実に成長しています。2023年の13億米ドルから2024年には13億4,000万米ドルへと、CAGR2.7％で拡大します。過去の期間に観察された成長は、診断法の進歩、疾患に対する認知度の向上、薬物療法の開発と承認、ヘルスケア支出の増加、ヘルスケア分野における政府の取り組みや資金提供など、さまざまな要因によるものです。

肥大型心筋症（HCM）治療薬の市場規模は、今後数年間で安定した成長が見込まれます。2028年にはCAGR2.6％で14億8,000万米ドルに成長します。予測期間中に予想される成長は、遺伝子研究や個別化医療、新しい治療法の出現、共同研究イニシアティブ、患者中心のヘルスケアモデルの採用、世界ヘルスイニシアティブに起因しています。予測期間に予想される主な動向には、標的治療、個別化医療、遺伝子検査の進歩、医薬品パイプラインの拡大、共同研究やパートナーシップの増加、患者中心のアプローチへの注目などがあります。

肥大型心筋症（HCM）治療薬市場の成長は、心血管疾患（CVD）の有病率の増加によって促進されると予測されます。CVDとは、心臓や血管に影響を及ぼす病態を指し、心房細動、心室細動、房室ブロックなどの不整脈を含み、長時間のモニタリングが必要となります。肥大型心筋症の治療薬は主に、高リスク患者における症状の緩和と心臓突然死の予防を目的としています。米国疾病予防管理センター（CDCP）の2022年10月の報告書によると、米国では36秒に1人が心血管疾患で死亡しており、2021年には米国だけで約83万6546人が死亡しています。このように、CVDの罹患率の上昇は肥大型心筋症（HCM）治療薬市場の原動力となっています。

臨床試験の急増が肥大型心筋症（HCM）治療薬市場の成長をさらに促進すると予想されます。臨床試験とは、新しい治療法、薬剤、介入の安全性、有効性、潜在的な副作用を評価する体系的な調査であり、肥大型心筋症（HCM）治療薬の有効性を評価する上で重要な役割を果たします。Xtalksの報告によると、2023年5月現在、ClinicalTrials.govに登録されている臨床試験は世界全体で452,604件であり、2021年初頭に記録された365,000件から顕著に増加しています。したがって、臨床試験の増加は肥大型心筋症（HCM）治療薬市場を推進する重要な要因となっています。

2023年の肥大型心筋症（HCM）治療薬市場で最大の地域は北米でした。アジア太平洋は、肥大型心筋症（HCM）治療薬市場レポートにおいて予測期間中に最も急成長する地域となる見込みです。肥大型心筋症（HCM）治療薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 肥大型心筋症（HCM）治療薬市場の特徴

第3章 肥大型心筋症（HCM）治療薬市場の動向と戦略

第4章 肥大型心筋症（HCM）治療薬市場- マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の肥大型心筋症（HCM）治療薬市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 肥大型心筋症（HCM）治療薬市場セグメンテーション

  • 世界の肥大型心筋症（HCM）治療薬市場、薬剤タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 抗不整脈薬
  • 抗凝固剤
  • ベータアドレナリン遮断薬
  • カルシウムチャネルブロッカー
  • その他
  • 世界の肥大型心筋症（HCM）治療薬市場、デバイスタイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 除細動器
  • ペースメーカー
  • その他
  • 世界の肥大型心筋症（HCM）治療薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • クリニック

第7章 肥大型心筋症（HCM）治療薬市場の地域および国分析

  • 世界の肥大型心筋症（HCM）治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の肥大型心筋症（HCM）治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋の肥大型心筋症（HCM）治療薬市場

第9章 中国の肥大型心筋症（HCM）治療薬市場

第10章 インドの肥大型心筋症（HCM）治療薬市場

第11章 日本の肥大型心筋症（HCM）治療薬市場

第12章 オーストラリアの肥大型心筋症（HCM）治療薬市場

第13章 インドネシアの肥大型心筋症（HCM）治療薬市場

第14章 韓国の肥大型心筋症（HCM）治療薬市場

第15章 西欧の肥大型心筋症（HCM）治療薬市場

第16章 英国の肥大型心筋症（HCM）治療薬市場

第17章 ドイツの肥大型心筋症（HCM）治療薬市場

第18章 フランスの肥大型心筋症（HCM）治療薬市場

第19章 イタリアの肥大型心筋症（HCM）治療薬市場

第20章 スペインの肥大型心筋症（HCM）治療薬市場

第21章 東欧の肥大型心筋症（HCM）治療薬市場

第22章 ロシアの肥大型心筋症（HCM）治療薬市場

第23章 北米の肥大型心筋症（HCM）治療薬市場

第24章 米国の肥大型心筋症（HCM）治療薬市場

第25章 カナダの肥大型心筋症（HCM）治療薬市場

第26章 南米の肥大型心筋症（HCM）治療薬市場

第27章 ブラジルの肥大型心筋症（HCM）治療薬市場

第28章 中東の肥大型心筋症（HCM）治療薬市場

第29章 アフリカの肥大型心筋症（HCM）治療薬市場

第30章 肥大型心筋症（HCM）治療薬市場の競合情勢と企業プロファイル

  • 肥大型心筋症（HCM）治療薬市場の競合情勢
  • 肥大型心筋症（HCM）治療薬市場の企業プロファイル
    • Merck &Co. Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG

第31章 世界の肥大型心筋症（HCM）治療薬市場の競合ベンチマーキング

第32章 世界の肥大型心筋症（HCM）治療薬市場競争ダッシュボード

第33章 肥大型心筋症（HCM）治療薬市場における主要な合併と買収

第34章 肥大型心筋症（HCM）治療薬市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r11043

“Hypertrophic Cardiomyopathy (HCM) Therapeutics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hypertrophic cardiomyopathy (him) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hypertrophic cardiomyopathy (him) therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The hypertrophic cardiomyopathy (him) therapeutics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug Type: Antiarrhythmic Agents; Anticoagulants; Beta Adrenergic Blocking Agents; Calcium Channel Blockers; Other Drug Types
  • 2) By Device Type: Defibrillators; Pacemakers; Other Device Types
  • 3) By End User: Hospitals; Clinics
  • Companies Mentioned: Merck & Co. Inc.; Pfizer Inc.; Sanofi SA; Teva Pharmaceutical Industries Ltd.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Hypertrophic cardiomyopathy (HCM) therapeutics refer to the treatment of a condition characterized by the abnormal thickening (hypertrophy) of the heart muscle, leading to impaired blood-pumping efficiency. The goal of hypertrophic cardiomyopathy therapeutics is to alleviate symptoms and prevent sudden cardiac death, particularly in high-risk patients.

The primary drug types used in hypertrophic cardiomyopathy therapeutics include antiarrhythmic agents, anticoagulants, beta-adrenergic blocking agents, calcium channel blockers, and others. Antiarrhythmic agents are medications designed to address abnormal heart rhythms or arrhythmias. Additionally, various devices, such as defibrillators, pacemakers, and others, are employed in hospitals and clinics as part of the therapeutic approach to managing hypertrophic cardiomyopathy.

The hypertrophic cardiomyopathy (HCM) therapeutics market research report is one of a series of new reports from The Business Research Company that provides hypertrophic cardiomyopathy (HCM) therapeutics market statistics, including hypertrophic cardiomyopathy (HCM) therapeutics industry global market size, regional shares, competitors with hypertrophic cardiomyopathy (HCM) therapeutics market share, detailed hypertrophic cardiomyopathy (HCM) therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the hypertrophic cardiomyopathy (HCM) therapeutics industry. This hypertrophic cardiomyopathy (HCM) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hypertrophic cardiomyopathy (hcm) therapeutics market size has grown steadily in recent years. It will grow from $1.3 billion in 2023 to $1.34 billion in 2024 at a compound annual growth rate (CAGR) of 2.7%. The growth observed in the historical period can be attributed to various factors, including advancements in diagnostics, increased awareness of the disease, developments and approvals in drug therapies, a rise in healthcare expenditure, and government initiatives and funding in the healthcare sector.

The hypertrophic cardiomyopathy (hcm) therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.48 billion in 2028 at a compound annual growth rate (CAGR) of 2.6%. The anticipated growth in the forecast period can be attributed to genetic research and personalized medicine, the emergence of new therapeutic modalities, collaborative research initiatives, the adoption of patient-centric healthcare models, and global health initiatives. Major trends expected in the forecast period include advancements in targeted therapies, personalized medicine, and genetic testing, the expansion of drug pipelines, increased collaborations and partnerships, and a focus on patient-centric approaches.

The growth of the hypertrophic cardiomyopathy (HCM) therapeutics market is anticipated to be propelled by the increasing prevalence of cardiovascular diseases (CVD). CVD refers to conditions affecting the heart or blood vessels, encompassing irregularities such as atrial fibrillation, ventricular fibrillation, and atrioventricular block, necessitating prolonged monitoring. Therapeutics for hypertrophic cardiomyopathy primarily aim to alleviate symptoms and prevent sudden cardiac death in high-risk patients. According to the October 2022 report from the Center for Disease Control and Prevention (CDCP), one person succumbs to cardiovascular disease in the United States every 36 seconds, contributing to nearly 836,546 deaths in the country alone in 2021. Thus, the rising incidence of CVD serves as a driving force for the hypertrophic cardiomyopathy (HCM) therapeutics market.

The surge in clinical trials is expected to further drive the growth of the hypertrophic cardiomyopathy (HCM) therapeutics market. Clinical trials, systematic investigations assessing the safety, efficacy, and potential side effects of new medical treatments, drugs, or interventions, play a crucial role in evaluating the effectiveness of Hypertrophic Cardiomyopathy (HCM) Therapeutics. As of May 2023, there were 452,604 registered clinical trials globally on ClinicalTrials.gov, as reported by Xtalks, indicating a notable increase from the 365,000 trials recorded in early 2021. Therefore, the escalation in clinical trials is a significant factor propelling the hypertrophic cardiomyopathy (HCM) therapeutics market.

A key trend gaining traction in the hypertrophic cardiomyopathy (HCM) therapeutics market is product innovation. Major players in the cardiomyopathy therapeutics sector are actively involved in developing innovative products to enhance their market position. In April 2022, Bristol Myers Squibb, a U.S.-based biopharmaceutical company, introduced Camzyos (mavacamten), an oral small-molecule cardiac myosin inhibitor for treating hypertrophic cardiomyopathy (HCM) and heart diastolic dysfunction diseases. FDA-approved for adults with symptomatic class II-III obstructive hypertrophic cardiomyopathy, Camzyos is the first and only allosteric and reversible inhibitor of cardiac myosin, addressing the underlying pathophysiology of obstructive HCM by controlling the number of myosin heads entering power-generating states on actin.

Leading companies in the hypertrophic cardiomyopathy (HCM) therapeutics market are focused on developing breakthrough therapies such as next-generation cardiac myosin inhibitors, aiming to provide significant improvements over existing treatments. These inhibitors, a novel class of therapeutic agents, selectively target and inhibit cardiac myosin, a protein crucial for muscle contraction. For example, in December 2021, Cytokinetics Incorporated, a U.S.-based biopharmaceutical company, received FDA breakthrough therapy designation for aficamten, its next-generation cardiac myosin inhibitor designed to treat symptomatic obstructive hypertrophic cardiomyopathy. Aficamten demonstrated substantial reductions in left ventricular outflow tract pressure gradients and improved symptoms, earning recognition for its potential to surpass existing therapies.

In June 2021, Nordic Capital, a Sweden-based private equity investment firm, acquired ADVANZ PHARMA for $846 million. This strategic acquisition aims to support ADVANZ PHARMA's growth in supplying complex medicines in Europe, with the potential for cost savings in healthcare systems. ADVANZ PHARMA Corp. Limited, a UK-based specialty pharmaceutical company, focuses on providing complex medicines across therapeutic areas such as hepatology, gastroenterology, anti-infectives, critical care, endocrinology, and CNS.

Major companies operating in the hypertrophic cardiomyopathy (hcm) therapeutics market report are Merck & Co. Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc, Gilead Sciences Inc., Bayer AG, Correvio Pharma Corp., Abbott Laboratories Inc., Advanz Pharma Corp., Lupin Limited, Myokardia Inc., Boston Scientific Corporation, Bristol-Myers Squibb Company, Johnson & Johnson, Medtronic plc, Mylan N.V., Cardiome Pharma Corp., Cytokinetics Inc., Daiichi Sankyo Company Limited, GlaxoSmithKline plc., HUYA Bioscience International LLC, Ionis Pharmaceuticals Inc., Janssen Pharmaceuticals Inc., Kowa Company Ltd., Luitpold Pharmaceuticals Inc., Menarini Group, Mitsubishi Tanabe Pharma Corporation, Nippon Shinyaku Co. Ltd., Otsuka Holdings Co. Ltd., Servier Laboratories, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited .

North America was the largest region in the hypertrophic cardiomyopathy (HCM) therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the hypertrophic cardiomyopathy (HCM) therapeutics market report during the forecast period. The regions covered in the hypertrophic cardiomyopathy (hcm) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hypertrophic cardiomyopathy (hcm) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hypertrophic cardiomyopathy (HCM) therapeutics market consists of revenues earned by entities by provide progressive disease management, physical therapy (PT), and occupational therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypertrophic cardiomyopathy (HCM) therapeutics market also consists of sales of disopyramide, wearable heart monitoring devices, and cardiac rhythm management (CRM) devices which are used in providing hypertrophic cardiomyopathy (HCM) therapeutics services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Characteristics

3. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Trends And Strategies

4. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size and Growth

  • 5.1. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Segmentation

  • 6.1. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Antiarrhythmic Agents
  • Anticoagulants
  • Beta Adrenergic Blocking Agents
  • Calcium Channel Blockers
  • Other Drug Types
  • 6.2. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Defibrillators
  • Pacemakers
  • Other Device Type
  • 6.3. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics

7. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Regional And Country Analysis

  • 7.1. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 8.1. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 9.1. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
  • 9.2. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 10.1. India Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 11.1. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
  • 11.2. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 12.1. Australia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 13.1. Indonesia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 14.1. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
  • 14.2. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 15.1. Western Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
  • 15.2. Western Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 16.1. UK Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 17.1. Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 18.1. France Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 19.1. Italy Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 20.1. Spain Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 21.1. Eastern Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
  • 21.2. Eastern Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 22.1. Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 23.1. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
  • 23.2. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 24.1. USA Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
  • 24.2. USA Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 25.1. Canada Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
  • 25.2. Canada Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 26.1. South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
  • 26.2. South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 27.1. Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 28.1. Middle East Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
  • 28.2. Middle East Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

  • 29.1. Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
  • 29.2. Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Competitive Landscape
  • 30.2. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Company Profiles
    • 30.2.1. Merck & Co. Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Pfizer Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Sanofi SA
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Teva Pharmaceutical Industries Ltd.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Competitive Benchmarking

32. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

34. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Future Outlook and Potential Analysis

  • 34.1 Hypertrophic Cardiomyopathy (HCM) Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Hypertrophic Cardiomyopathy (HCM) Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Hypertrophic Cardiomyopathy (HCM) Therapeutics Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer